Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Abiraterone triplet therapy improves long-term survival in metastatic prostate cancer (opens in a new tab)

news-medical.net · 2026-10-24

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

18 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Cited as backgroundpresented as the new finding

    https://www.esmo.org/press-releases/adding-abiraterone-to-adt-and-docetaxel-improves-survival-in-metastatic-prostate-cancer

    Where the story links (opens in a new tab)
The literature search

18 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 14 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 9Not checkedAdding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification.View evidenceHide evidence

As statedlasting survival benefit

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 9Not checkedThe findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.View evidenceHide evidence

As statedalmost eight years of follow-up

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 9Not checkedThe PEACE-1 trial included 1,173 men with de novo metastatic castration-sensitive prostate cancer, and all received standard of care with or without docetaxel before random assignment to additional treatments including abiraterone plus prednisone.View evidenceHide evidence

As stated1,173 men

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 9Not checkedAfter a median follow-up of 7.7 years, adding abiraterone reduced the risk of death by 25% (HR 0.75; 95% CI 0.65-0.87; p=0.0001), with median overall survival of 6.1 years versus 4.6 years without it.View evidenceHide evidence

As stated25% reduction in risk of death; 6.1 years vs 4.6 years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 9Not checkedAmong the 710 men who received ADT plus docetaxel, adding abiraterone plus prednisone reduced the risk of death by 32% (HR 0.68; 95% CI 0.56-0.82), with median survival of 6.2 years versus 4.4 years and 40.3% versus 27.1% alive at eight years.View evidenceHide evidence

As stated32% reduction in risk of death; 6.2 years vs 4.4 years; 40.3% vs 27.1% alive at eight years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 9Not checkedThe survival benefit of triplet therapy did not differ significantly by extent of disease, and the benefit was seen in both high-volume and low-volume disease analyses.View evidenceHide evidence

As statedinteraction test p=0.56

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 7 of 9Not checkedNo new long-term safety concerns were identified, although grade 3-4 high blood pressure and low potassium were more common with triplet therapy than with doublet therapy.View evidenceHide evidence

As stated21% vs 14% high blood pressure; 4% vs 1% low potassium

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 8 of 9Not checkedThe investigators suggest that the fact that most men in the control groups later received an androgen receptor pathway inhibitor supports starting treatment early rather than waiting until progression.View evidenceHide evidence

As stated86% later received an ARPI

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 9 of 9Not checkedThe article says PEACE-1 did not directly compare triplet therapy with ADT plus a newer hormone therapy without chemotherapy, and that it remains unclear which patients gain the greatest additional benefit from chemotherapy.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Explore all search results